GAINESVILLE, Fla. and CAMBRIDGE, Mass. , May 05, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , May 04, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the
-Company remains on track to present additional 12-month data from the XLRP and achromatopsia clinical trials in the second quarter of 2021- ALACHUA, Fla. and CAMBRIDGE, Mass. , May 03, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , April 29, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , April 26, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
-Technology To Be Incorporated In Multiple SparingVision SAS Programs- ALACHUA, Fla. and CAMBRIDGE, Mass. , April 19, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene
- AGTC Transfers Clinical Trial Materials and Phase 1/2 Data To TeamedON - ROCKVILLE, Md. , April 13, 2021 (GLOBE NEWSWIRE) -- TeamedOn International, Inc. , a biotechnology company dedicated to advancing gene therapies for rare diseases, including ophthalmic indications, and Applied Genetic
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , March 31, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
-AGTC’s deep commitment to the patient voice drives solutions to support patient access to information and to improve the experience of patients participating in clinical trials- GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , March 25, 2021 (GLOBE NEWSWIRE) -- Applied Genetics Technologies Corporation
-AGTC will highlight the value of the patient voice in gene therapy development- GAINESVILLE, Fla. and CAMBRIDGE, Mass. , March 18, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus
